Mass exits spell out support prices in the foreseen future.

$Cybin (CYBN.US)$ , it's time to start climbing back up. The acquisition of Small Pharma should be a solidifying factor, not a purpose for decline.

However, all of my research indicates that this isn't the bottom of the barrel just yet for Cybin. We may head into the support range before we start working our way back up the totem pole.